What is the market's earnings forecast for Vaxcyte next quarter?

What is the revenue and EPS growth rate for Vaxcyte year over year?

What were the key takeaways from Vaxcyte's earnings call?

What were the key takeaways from Vaxcyte’s earnings call?

What is Vaxcyte's gross profit margin?

What does Vaxcyte do and what are its main business segments?

What factors drove the changes in Vaxcyte's revenue and profit?

What guidance did Vaxcyte's management provide for the next earnings period?

- **Phase III Trials Initiated**: OPUS-1, -2, -3 trials underway for VAX-31, targeting 6,000 adults to demonstrate noninferiority and broader serotype coverage.
- **Manufacturing Readiness**: $1B U.S. facility completed; commercial supply buildup underway for potential 2027 launch.
- **Financial Strength**: $2.4B cash post-equity offering; 2026 R&D expenses to rise for clinical and manufacturing scale-up.
- **Group A Strep Resumption**: Phase I safety study starting in adults, with potential for pediatric efficacy trials.
- **Competitive Edge**: 31-valent coverage vs. 20/21-valent competitors; focus on immune response superiority and serotype expansion.

**【CEO Summary Section】**
- **PCV Franchise Momentum**: Highlighted the adult PCV market growth driven by expanded age recommendations and international adoption. VAX-31 Phase III trials (OPUS-1, -2, -3) are underway, targeting safety, immunogenicity, and broader serotype coverage. Infant program modifications include optimized dose arms for enhanced immune responses.
- **Manufacturing & Commercial Readiness**: Completed a $1B U.S. manufacturing facility and appointed Chief Commercial Officer Mike Mullette to lead launch planning. Financial strength includes a $2.4B cash balance post-equity offering.

**【CFO Financial Commentary】**
- **Financial Position**: Ended 2025 with $2.4B in cash, bolstered by a $600M equity offering. 2026 R&D expenses expected to rise due to clinical trial expansion and manufacturing scale-up. Capitalized costs for the dedicated facility are declining.
- **Expense Outlook**: Total expenses, especially R&D, will increase to support Phase III trials and commercial supply buildup.

**【Q&A Key Highlights】**
- **OPUS-1 Trial Design**: Powered for noninferiority against Prevnar 20 and Capvaxive, with flexibility to demonstrate coverage advantage over 10+ incremental serotypes. FDA alignment on manufacturing consistency study expected to support BLA submission.
- **Group A Strep (VAX-A1)**: Resumed Phase I safety study in adults, targeting immunogenicity and potential efficacy in children. Long-term goal is a Phase III efficacy trial.
- **Competitive Landscape**: VAX-31's 31-valent coverage vs. 20/21-valent competitors; monitoring GSK's 30-valent and Pfizer's 25-valent programs. Emphasis on coverage breadth and immune response superiority.
- **Commercial Strategy**: Catch-up recommendation potential for adults previously vaccinated with lower-valency PCVs. OPUS-3 trial data to support expanded use cases.

Vaxcyte, Inc.(PCVX)-20260225-2025 Q4 Earnings call transcript

- **VAX-31 adult success**: FDA Breakthrough Designation for VAX-31 with superior immune responses vs. PCV20, Phase III starting mid-2025.
- **Infant pipeline momentum**: VAX-24 infant Phase II data Q1 2025, VAX-31 infant study on track for 2026 readout.
- **Financial strength**: $3.13B cash, 2025 R&D spend up 50% to support launches and pipeline.
- **Manufacturing readiness**: Lonza facility 60-70% complete, targeting 2025 commercial readiness.
- **Innovative pipeline**: VAX-A1 Group A Strep vaccine leveraging proven conjugation technology.

**【CEO Summary Section】**
- VAX-31 adult Phase I/II data demonstrated superior immune responses across 31 serotypes, with high dose showing statistically higher responses for 7 of 20 shared serotypes vs. PCV20. FDA granted Breakthrough Therapy Designation for VAX-31 in adults.
- VAX-24 infant Phase II study fully enrolled (802 participants), with primary series data expected Q1 2025 and booster data Q4 2025. VAX-31 infant Phase II underway, targeting mid-2026 for key data.
- Pipeline expansion includes VAX-A1 for Group A Strep, with manufacturing scale-up progressing.

**【CFO Financial Commentary】**
- $3.13B cash as of Dec 31, 2024, including $2.2B from 2024 equity raises. 2025 R&D expenses expected to increase ~50% YoY, driven by:
  - $127.8M in 2024 capital expenditures for Lonza manufacturing build-out (60-70% of $300-350M total)
  - Inventory build for adult launch
  - VAX-31 adult Phase III initiation
- Manufacturing facility on track for early 2025 completion, supporting global commercial supply.

**【COO Clinical Development】**
- VAX-31 adult Phase III pivotal non-inferiority study to start mid-2025, with top line data expected 2026. Full Phase III program to read out 2026-2027.
- VAX-24 infant Phase II post-dose 3 IgG seroconversion data expected Q1 2025, with non-inferiority margin of 10% absolute points. VAX-31 infant Phase II data expected mid-2026.
- Group A Strep vaccine VAX-A1 in preclinical development, leveraging site-specific conjugation technology for broad coverage.

**【Q&A Key Themes】**
- **VAX-24 Infant Data Timing**: Primary series data Q1 2025 will include safety through post-dose 3, with booster data Q4 2025. Non-inferiority misses (e.g., 6/20 serotypes) possible but unlikely given adult data continuity.
- **Manufacturing Capacity**: Lonza facility on track for 2025 completion, with commercial launch readiness for VAX-31 adult.
- **Policy Risks**: Bipartisan support for vaccines observed, with no direct threats to PCV schedules identified.
- **Group A Strep Vaccine**: VAX-A1 leveraging same platform as PCVs, with IND-enabling studies nearing completion.

Actual	-1.72	-0.41	-0.41	-0.41	-0.46	-0.51	-0.55	-0.68	-0.8	-0.93	-1.03	-0.7	-0.7	-0.91	-1.83	-0.85	-1.1	-0.83	-1.02	-1.04	-1.22	-1.81
Forecast	-1.2667	-0.4433	-0.54	-0.51	-0.5233	-0.5467	-0.56	-0.6267	-0.69	-0.8367	-0.93	-0.8221	-0.745	-0.8377	-1.0544	-1.1288	-0.9756	-1.1008	-1.1065	-1.0614	-1.16	-1.5297
Surprise	-35.79%	+7.51%	+24.07%	+19.61%	+12.10%	+6.71%	+1.79%	-8.50%	-15.94%	-11.15%	-10.75%	+14.85%	+6.04%	-8.63%	-73.56%	+24.70%	-12.75%	+24.60%	+7.82%	+2.02%	-5.17%	-18.32%

Actual	0	0	--	0	0	0	--	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Forecast	166.67K	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Surprise	-100.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%

PCVX

PCVX fundamentals

PCVX Q4 2025 Earnings

Earnings Call

You can ask Aime

PCVX

PCVX fundamentals

PCVX Q4 2025 Earnings

Earnings Call

PCVX Earnings Call Summary for Q4/20254:30 PM on Feb 24, 2026

PCVX Earnings Call Summary for Q2/2025 Apr 1, 2026

PCVX Earnings Call Summary for Q1/2025 Apr 1, 2026

PCVX Earnings Call Summary for Q4/20244:30 PM on Feb 25, 2025

PCVX Earnings Call Summary for Q3/2024 Apr 1, 2026

You can ask Aime